Sanofi

01/02/2024
01/02/2024
Institution
Download as PDF
Institution identification

Institution ID

3331359

Institution full name and acronym

Sanofi

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A drug utilization study (DUS) of alirocumab in Europe to assess the effectiveness of the dosing recommendation to avoid very low LDL-C levels
A non-interventional, observational study in Germany to evaluate the effectiveness of reversal of local anesthesia and occurrence of adverse events in patients treated with OraVerse® in dental office (OraNIS)
A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) study
A Pregnancy Registry to Evaluate the Safety of Dengue Vaccine among Inadvertently Exposed Pregnant Women and their Offsprings
A prospective multicenter observational post authorization safety sub-registry to characterize the long-term safety profile of commercial use of eliglustat (Cerdelga®) in adult patients with Gaucher disease (ELISAFE)
A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune-Mediated Reactions with Alglucosidase Alfa Treatment (Pompe Safety Sub-Registry)
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) (GZ402673-OBS13434)
A Retrospective study to analyse the treatment outcomes of patients with severe atopic dermatitis (AD) who were enrolled in the Early Access to Medicines Scheme (EAMS) for dupilumab
A Survey of Healthcare Professionals in Europe to Evaluate the Effectiveness of the ENJAYMO™ Physician’s Guide
Actual conditions of use of OraVerse® in patients among resident dentists throughout Germany (OraDUS)
An assessment of physician knowledge and understanding of the risks of vandetanib (Caprelsa®) within the European Union
Behavior and knowledge survey to assess the effectiveness of educational materials among healthcare professionals who prescribe AUBAGIO® (teriflunomide) (cross-sectional survey)
Behavior and knowledge survey to assess the effectiveness of educational materials in patients treated with AUBAGIO® (teriflunomide) (cross-sectional survey)
Building a pregnancy pharmacovigilance model for the future: Can pregnancy data collected by ConcePTION partners be analysed using common standards developed by the ConcePTION project?
Clinical experience with cabazitaxel in patients with metastatic castrate resistant prostate cancer (ECLIPSE) (ELIPSE)
Concomitant use of dronedarone and digoxin (or statins) and the risk of digitalis intoxication (or rhabdomyolysis and myopathy)-- a post-marketing cohort study using the US Clinformatics DataMart® (formerly LabRx®) database
Drug Utilization Study of eliglustat in the US population using MarketScan® Database (ELIGLC06912)
Effectiveness evaluation of the local additional risk minimisation measures for STAMARIL® in the United Kingdom: a survey for healthcare professionals and vaccinees
Fabrazyme (agalsidase beta) home infusion educational materials effectiveness evaluation: a survey for healthcare providers and patients/caregivers (Fabrazyme Home Infusion Ed Mat Survey)
International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis (OBS13436)
International Observational, Study to Evaluate the Benefit/Risk of Vandetanib (Caprelsa™) 300 mg in RET Mutation Negative and RET Mutation Positive Patients with Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer (Caprelsa 104)
Knowledge survey to assess the effectiveness of educational materials among healthcare professionals who prescribe Lemtrada® (alemtuzumab)
Knowledge survey to assess the effectiveness of educational materials among patients prescribed LEMTRADA® (alemtuzumab)
Monitoring the safety of alirocumab in HIV patients: A Post-Authorization Safety Study Using Healthcare Databases
Non-interventional post-authorization study on effectiveness of reversal of local anaesthesia and on the occurrence of local reactions and cardiovascular adverse events in patients treated with OraVerse® versus patients not treated with OraVerse® (control group) in Germany (ORAPAES)
PaTernal exposure to vAlproate, further iNvestiGation on the risk of NeuroDevelopmental Disorders (NDD) and Major Congenital Malformation (MCM) in Offspring: A Non-Interventional Post-Authorization Safety Study (TANGO)
POST AUTHORIZATION SAFETY STUDY OF FEXINIDAZOLE FOR HUMAN AFRICAN TRYPANOSOMIASIS : Analysis of real-life safety and effectiveness data on fexinidazole, collected by NSSCP & WHO as part of NSSCP activity as per WHO interim guidelines 2019 (FEXINC09395)
Post-Authorization Safety Study Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine (DNG15-Post Authorisation safety Surveillance study)
Post-authorization Safety Surveillance Program for Sarilumab using existing European Rheumatoid Arthritis Registries in Germany, Spain, Sweden and United Kingdom
Prevalence of immunology testing in patients treated with alglucosidase alfa with significant hypersensitivity/anaphylactic reactions (ALGMYC07390)
Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP® administered in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer in current clinical practice: A Post-Authorisation Safety Study (PASS) (OZONE)
Prospective, observational cohort, evaluating the incidence of nephrotoxicity, and other adverse events of interest, in patients treated with the higher recommended teicoplanin loading dose (12 mg/kg twice a day), and comparison with external historical comparator data (OBS13842)
Serious Liver Injury and Interstitial Lung Disease Occurrences in Patients Diagnosed with Atrial Fibrillation Treated with Selected Antiarrhythmics
SURVEY TO EVALUATE THE KNOWLEDGE AND UNDERSTANDING OF THE KEY SAFETY MESSAGES IN THE HEALTHCARE PROFESSIONAL GUIDE AND THE PATIENT GUIDE FOR SULIQUA
The MenQuadfi™ Pregnancy Registry: A surveillance registry to assess the safety of MenQuadfi™ among exposed pregnant women and their offspring (MEQ00070)
WP6 negative control study: The risk of myocardial infarction not associated with the use of antibiotics: A study using a US database
WP6 replication study: The risk of liver injury associated with the use of antibiotics: A study using a US database with linkage with hospital data